Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data sought on new prostate cancer drug

NCT ID NCT07093801

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 300 men with a type of advanced prostate cancer that no longer responds to hormone therapy. Participants receive a targeted radiation treatment called lutetium-177 vipivotide tetraxetan as part of their normal care. Researchers will track how long the cancer stays under control and how patients fare over time, without changing or interfering with their treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with mCRPC eligible for and prescribed with lutetium (177Lu) vipivotide tetraxetan

Ages

18 to 99 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Adult patients diagnosed with mCRPC eligible for and prescribed with lutetium (177Lu) vipivotide tetraxetan by the treating physician (Multidisciplinary Team). 2. ≥ 18 years old at the time of enrollment. 3. Written informed consent must be obtained to participate to this study In addition to the above-listed criteria, no other inclusion/exclusion criteria exist other than the requirements stated in the local Summary of Product Characteristics (SmPC) and in the "Scheda di Monitoraggio AIFA", e.g., contraindications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic castration resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic castration resistant prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    34 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Alessandria, AL, 15121, Italy

  • Novartis Investigative Site

    RECRUITING

    Asti, AT, 14100, Italy

  • Novartis Investigative Site

    RECRUITING

    Bergamo, BG, 24127, Italy

  • Novartis Investigative Site

    RECRUITING

    Brescia, BS, 25123, Italy

  • Novartis Investigative Site

    RECRUITING

    Catania, CT, 95123, Italy

  • Novartis Investigative Site

    RECRUITING

    Meldola, FC, 47014, Italy

  • Novartis Investigative Site

    RECRUITING

    Cona, FE, 44124, Italy

  • Novartis Investigative Site

    RECRUITING

    Foggia, FG, 71122, Italy

  • Novartis Investigative Site

    RECRUITING

    Florence, FI, 50134, Italy

  • Novartis Investigative Site

    RECRUITING

    Genova, GE, 16128, Italy

  • Novartis Investigative Site

    RECRUITING

    Genova, GE, 16132, Italy

  • Novartis Investigative Site

    RECRUITING

    Latina, LT, 04100, Italy

  • Novartis Investigative Site

    RECRUITING

    Province of Macerata, MC, 62100, Italy

  • Novartis Investigative Site

    RECRUITING

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    RECRUITING

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    RECRUITING

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    RECRUITING

    Palermo, PA, 90146, Italy

  • Novartis Investigative Site

    RECRUITING

    Padova, PD, 35128, Italy

  • Novartis Investigative Site

    RECRUITING

    Perugia, PG, 06129, Italy

  • Novartis Investigative Site

    RECRUITING

    Pisa, PI, 56126, Italy

  • Novartis Investigative Site

    RECRUITING

    Aviano, PN, 33081, Italy

  • Novartis Investigative Site

    RECRUITING

    Rionero in Vulture, PZ, 85028, Italy

  • Novartis Investigative Site

    RECRUITING

    Reggio Emilia, RE, 42123, Italy

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00128, Italy

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00152, Italy

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00168, Italy

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00189, Italy

  • Novartis Investigative Site

    RECRUITING

    La Spezia, SP, 19121, Italy

  • Novartis Investigative Site

    RECRUITING

    Taranto, TA, 74100, Italy

  • Novartis Investigative Site

    RECRUITING

    Torino, TO, 10128, Italy

  • Novartis Investigative Site

    RECRUITING

    Mestre, VE, 30174, Italy

  • Novartis Investigative Site

    RECRUITING

    Negrar, VR, 37024, Italy

  • Novartis Investigative Site

    RECRUITING

    Milan, 20141, Italy

  • Novartis Investigative Site

    RECRUITING

    Naples, 80131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.